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Abstract
Transdermal delivery system was one of the few novel drug delivery systems to taste commercial success. With the launch of scopolamine and estradiol patches and their immense popularity among the users, the field of transdermal delivery has become a potential area for the formulation scientists. The subsequent investigation into the feasibility of many drugs to be delivered via the transdermal route was marred by failures. This led researchers to rethink about the formidable barrier properties of the skin vis-?-vis the physicochemical and biological properties of the skin. The improvements in biophysical techniques aided researchers to understand better, the various aspects involved in the transdermal delivery of the drugs. It is at this stage that the general rules were stipulated for the physicochemical properties of the drugs to be delivered via the transdermal route. It was generally agreed upon that the route is suitable for low dose, small molecular weight drugs with balanced oil-water partitioning properties. 
However, ways to circumvent the barrier property of the skin to make possible the effective delivery of drugs, which do not fall into this category, has been the subject of immense interest. While physical techniques were popular for modulated delivery of macromolecular drugs, chemical enhancement strategies continue to dominate the field of transdermal delivery of low molecular weight drugs. The ease of incorporation of these chemical enhancers into the dosage form makes it an attractive option. Hence development of new chemical entities that increase the solubility/diffusivity / partition coefficient of drug into the skin to be effective permeation enhancers were devised. The scientists however had to confront the issue of immunogenicity of these agents with the ensuing complications. 
Co-enhancement strategies, not only made possible the effective and enhanced delivery of the drugs possible, but the formulation scientists could choose the magnitude of drug delivery by permutations and combinations of the different enhancers, thus conferring the issue of drug delivery with the dosage form and not the skin. The utility of 'Generally Recognized As Safe' (GRAS) enhancers in this regard need not be over emphasized. Several of these, which enhance drug delivery via different anatomical routes of the skin, have been employed as co-enhancers in co-enhancement strategy. These strategies were designed to be commercially viable as they bypass the lengthy investigative and regulatory processes required of a new chemical entity to be a safe and efficient transdermal enhancer. Novel formulations designed for the same purpose were of questionable utility due to problems in drug delivery, stability and cumbersome formulation process. Super saturated systems, which showed promise in terms of drug delivery, were of limited utility commercially due to stability problems. In this context, strategy employed in the current study has significant potential to be employed as transdermal reservoir as it is simple, safe and can be easily formulated. The optimized reservoir, if necessary, may be investigated for a more pulsatile form of delivery to match the chronopharmacokinetic requirements of the disease process. 
The study employed hydroxy propyl-b-cyclodextrin (HP-b-CD), known to be a safe solubility enhancer along with the commonly used solvents, ethanol and propylene glycol and surfactant, polysorbate 80 as transdermal enhancers. While cyclodextrins alone were widely reported to enhance the topical bioavailability of many drugs, the enhancement falls short of effective systemic transdermal delivery in many cases. Hence the effectiveness of co-enhancement strategy with either of the solvents (ethanol, propylene glycol) or the surfactant (polysorbate 80) in a HP-b-CD -based formulation was investigated for the transdermal delivery of lipophilic drugs. Lipophilic drugs with their poor aqueous solubility and their inability to partition into the hydrophilic viable epidermis from the lipophilic stratum corneum encounter difficulty while traversing the skin. To systematically investigate the feasibility of facilitated transdermal delivery via the present strategy, two lipophilic drugs, gliquidone and ketoprofen were chosen, with due attention not only to their physicochemical, but also pharmacological properties. Gliquidone was not investigated earlier for transdermal delivery or solubility enhancement by preparation of cyclodextrin complexes. On the other hand ketoprofen was investigated for both the purposes with some success, but there are no reports of HP-b-CD being used in a co-enhancement strategy to obtain enhanced transdermal performance of ketoprofen. Hence, the drugs and the chosen strategy are of relevance in the present day transdermal scenario. 
The foremost requirement of the study is to establish an interaction of the investigational drugs with the ligand HP-b-CD. The phase solubility studies were employed to establish the interaction in the liquid state. HP-b-CD increased the solubility of the two investigational drugs in a linear concentration dependant fashion suggesting the complex formation in a 1:1 ratio. The solid-state interaction of the drug with the ligand in complexes prepared by co-evaporation, co-lyophilization, kneading and physical mixing was also established by differential scanning calorimetry, X-ray diffraction and I.R. spectroscopic techniques. These studies unambiguously established the interaction of the two test drugs with HP-b-CD in amorphizing the drugs due to molecular encapsulation. The solid state interaction, though of limited relevance in the context of the present study, serves to further prove the interaction observed in the liquid state between the interacting molecules. 
The importance of pH in the transdermal delivery of ionizable drugs has been emphasized in earlier studies. The well-published pH partition theory suggests that unionized molecules are favored for transdermal delivery due to their better partitioning characteristics into the lipophilic stratum corneum. However, where the drug permeation is limited due to poor solubility, it was found that enhanced flux of drug could be obtained by adjusting the pH to improve the solubility of the drug in the donor phase. An ion pairing mechanism operative in the skin has been suggested for the better flux of the ionized species. 
pH also has significant implications in the complexation of drugs with the ligand, HP-b-CD. The prime requirement of the drug to be encapsulated in the molecular cavity of HP-b-CD being lipophilicity, it is natural for the unionized species of the drug to be favorably included over ionized species. Hence, it was believed that greater solubilization of the drugs can be achieved by controlling the pH to maintain the drug in an unionized state. However, recent studies addressing the issue of pH and ionization were encountered with opposite results where ionized complex of the drug was more soluble than the unionized drug complex. 
The present study explored the utility of pH as a co-enhancer in HP-b-CD based formulations for transdermal delivery. The solubility studies were conducted at different pH values in citrate- phosphate buffers. The results were interesting in that the two lipophilic drugs investigated showed better solubility and permeability characteristics in an ionized state. The comparison of the stability constants in the ionized and unionized state of the drug revealed a pattern consistent with earlier reports. While the stability constant of the ionized drug was lower than that of unionized drug, the higher solubility of the ionized drug in the presence of HP-b-CD can be attributed to the greater intrinsic solubility of the ionized drug species. 
The permeability of the ionized species of the drugs through the skin was known to be lower due to relatively limited lipophilicity of the ionized species and their lowered partitioning characteristics. The anionic form of gliquidone had an o/w partition coefficient of log P=2.9 at pH 7.0, which, hence did not presumably limit its permeability characteristics. Aided by the improved solubility, better permeation was obtained at an ionized state in the presence of HP-b-CD. In the case of ketoprofen, though the anionic form of the drug has a relatively lowered o/w partitioning (log P=1.28 at pH 6.0), an ion pairing mechanism operative in the skin may hold good in explaining the improved permeation of the drug. A similar trend was reported earlier with ibuprofen in the ionized form. 
The issue of how much HP-b-CD is optimum to achieve the desired flux of the investigational drugs has been investigated at different HP-b-CD concentrations. It has been observed that the drug concentration being maintained at saturation level in the donor reservoir is essential to maintain the improved flux of both gliquidone and ketoprofen. At saturation, the flux of the drugs increased near linearly with increasing concentration of HP-b-CD. However, a threshold was reached at 25% w/v HP-b-CD in case of gliquidone and 20% w/v in case of ketoprofen. Further increase in HP-b-CD concentration in the donor phase did not increase the flux. Hence in both the cases a lower concentration of HP-b-CD than required to achieve maximum flux was chosen to investigate the effect of co-enhancers. 
There were reports of HP-b-CD affecting the barrier properties of the stratum corneum by extracting the lipids. In the present study, however, the permeability characteristics of the two drugs remained unaffected by HP-b-CD as evident from the pre-treatment studies. Hence the enhancement obtained by HP-b-CD can be solely explained on the basis of solubility enhancement. 
Ethanol's function as a skin permeation enhancer was explained on the basis of increased solubility of the drug in the stratum corneum. Ethanol also affects the barrier properties of the skin in a concentration dependant fashion. While altering the permeability of the skin is the major mode of its action, for a poorly soluble drug, ethanol's function as a co-solvent can have significant implications in transdermal delivery when used alone and along with HP-b-CD. Earlier reports indicated that when ethanol was added to drug - HP-b-CD complex, the solubility of the drug decreases due to competitive inclusion of ethanol and dislodgement of the drug. It was necessary to investigate this pattern of solubility in the combined phase to clearly ascertain the role of ethanol in HP-b-CD based formulations. Hence, solubility studies were conducted at different compositions of HP-b-CD with increasing concentrations of ethanol with both gliquidone and ketoprofen. 
The profile was similar with both the drugs. The drug solubility decreased up to approximately 20% v/v alcohol due to competitive inclusion and the destabilizing effect of ethanol on the binary complex. Further increase in the concentration of ethanol enhanced the drug solubility due to exponential increase in the alcohol solubilized fraction and linear increase in the ternary complex formation. The relative contribution of each of the individual components ([D], the ethanol solubilized fraction, [DL], the drug- HP-b-CD binary complex and [DLC], the drug-ethanol- HP-b-CD ternary complex) to the total solubility of the drug in the presence of HP-b-CD and ethanol has been calculated based on the Li et al.'s mathematical postulate. 
The choice of the compositions investigated for in-vitro skin permeation studies were dependent on the solubility profile. It was indicated through these studies that while low concentrations of ethanol (< 20% v/v) reduced the solubility of the drug, at high concentration (80% v/v), HP-b-CD has only a marginal effect on the solubility of the drug, with major solubilized fraction being that of ethanol facilitated soluble species. The apparent effect of the solubility on the permeation of the drugs was evaluated by choosing the appropriate concentrations of the co-enhancer. 
When alcohol alone was the enhancer, the flux of both the drugs was enhanced. However, the increase in flux, in case of gliquidone, a more lipophilic drug was of a lower order compared to ketoprofen. The permeation profiles were also distinctly different with both the drugs. While the delivery of ketoprofen was Fickian, in case of gliquidone, the initial high permeation rate of the drug up to 6 hrs was followed by a slack phase. The results can possibly be explained by the difficulty of the highly lipophilic drug's partitioning into hydrophilic viable epidermis from the lipophilic stratum corneum, which acted as the rate-limiting step in case of gliquidone. However, with ethanol as a co-enhancer along with HP-b-CD, flux of both the drugs enhanced synergistically than when either of the enhancers was used alone. The predominant mechanism of action seems to be a result of solvent mediated effect of ethanol on the stratum corneum in allowing the permeation of the drug- HP-b-CD complex through the outer layers of the skin from where drug partitioning into the viable epidermis is facilitated by the carrier action of HP-b-CD. The pre-treatment studies also point towards increased permeation of the normally impermeable complex. 
Propylene glycol's action has been explained on the basis of its co-solvent properties that improve the thermodynamic activity of the drug. The solubility studies conducted at different volume fractions of propylene glycol with varied HP-b-CD concentrations present a picture similar to that of ethanol for both the drugs. The chosen propylene glycol fractions for permeation studies were based on the distinct difference between the individual species that account for the total solubility so as to show the difference between individual and co-enhancement strategy. 
Propylene glycol as a co-enhancer was effective in an additive fashion, with solubility enhancement as the predominant mechanism of transdermal enhancement. The partial role of solvent drag mechanism cannot be ruled out in case of ketoprofen, but seemed to have limited role in enhancing the flux of gliquidone. The discrepancy presumably was a result of the rate limiting effect of viable epidermis in the case of gliquidone, a drug with a higher lipophilicity. Pre-treatment studies did not suggest any alteration in the permeability characteristics of the skin due to the action of propylene glycol. 
With both the solvents as co-enhancers, the concentration of the co solvent has a vital role in defining the solubility and thus the permeability of the drugs. While too low a concentration of the co-solvent (< 20% v/v) reduces the solubility below that of using HP-b-CD alone, a too high concentration (80% v/v) allows no distinction from using the solvent as a single vehicle. Hence, the flux can be optimized using the middle concentrations of the co-solvent with fixed concentration of HP-b-CD to achieve an optimized flux. 
The influence of polysorbate-80 on the transdermal permeation of drugs was influenced by the action of surfactant on the integrity of the stratum corneum permitting greater quantities of the complex to permeate with the resultant enhancement in flux. While the solubility enhancement is of little significance in this context, the results of the solubility studies of the two drugs reveal a different pattern. While the presence of tween-80 and HP-b-CD does not influence the solubility of gliquidone beyond additive effect, the complexation constant of ketoprofen improved in the presence of tween-80. The difference can be explained on the basis of interaction of two co-enhancers permitting a ternary complex formation in the case of ketoprofen. With both the drugs the formulations did not show any significant difference in the lag time. 
The in-vivo studies performed allude to the enhancement trend witnessed in the in-vitro studies. The strategies were effective in enhancing the pharmacokinetic as well pharmacodynamic performance of both the drugs beyond that of single enhancers. More over, the strategy allows the flexibility of choosing the magnitude of delivery through choosing the relative concentrations of the co- enhancers. 
The absence of irritation and stability problems coupled with enhanced performance of the system is desirable of any formulation strategy. The HP-b-CD based co-enhancer formulations with their simple strategy and commonly used ingredients proved effective in promoting the transdermal delivery of the two investigational lipophilic drugs. It may be possible to adapt the strategy in general for transdermal delivery of other lipophilic drugs with an affinity to form molecular complexes with HP-b-CD, and thus increase the solubility and transdermal permeability. 
It is therefore concluded from the present investigation that 
? Gliquidone and ketoprofen interacted with HP-b-CD to form molecular complexes in a 1:1 ratio. ? In aqueous phase the solubility of the drugs increased linearly with HP-b-CD concentration. ? The steady state flux of both the drugs increased linearly with increase in HP-b-CD concentration, when the drug is present at saturated state. ? Enhanced transdermal permeation of both the drugs can be achieved by adjusting the pH of the donor/reservoir phase so that the drugs are in a more solubilized form. ? Ethanol as a co-enhancer along with HP-b-CD at particular concentrations increased the solubility and flux of gliquidone and ketoprofen synergistically. ? Propylene glycol enhanced the transdermal permeability of the drugs over and above the individual enhancers, but the effect is additive and largely reflective of improved solubility. ? Polysorbate- 80 enhanced the permeation of drugs synergistically with HP-b-CD by way of enhancing the membrane permeability. ? In-vivo studies proved that the reservoirs were efficient in allowing transdermal delivery of the drugs. ? The irritation potential of the reservoirs was negligible. ? The HP-b-CD based co-enhancer formulations improved the stability of gliquidone and ketoprofen. 
  	 


